Zoetis Inc. (0M3Q)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 80.97 |
|---|---|
| 52-week range | 68.58 – 147.79 |
| Return, 1 month / 3 months | +12.8% / +9.5% |
| Return, 1 year / 3 years | −43.4% / −49.7% |
| Trend | Below its 200-day average |
| RSI (14) | 71 |
| Volatility (1 year) | 39.3% |
| Worst drawdown (1 year) | -51.8% |
| Average daily value traded | 0.94M USD |
| Dividend yield | 2.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Zoetis is an animal health company that develops and makes medicines, vaccines and diagnostic products for pets and farm animals. Its customers include veterinarians, livestock producers and pet owners, who use its products to prevent and treat disease and to support animal health and productivity. The company is based in the United States and serves markets around the world through its animal health portfolio.
The shares are listed on the London Exchange in UK under the code 0M3Q, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Zoetis Inc. (0M3Q) trades on the London Exchange in UK. It last closed at USD 80.97 on 23 October 2026.
Its price-based Market X-Ray is 34 out of 100 (a weak price profile), ranking 2,916 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 43.4% and over the last three months it rose 9.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 16 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -13.8% | ||
| From 52-week high | -45.0% | ||
| Momentum | 32 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 9.5% | ||
| 6-month return | -29.1% | ||
| 12-month return, skipping the last month | -49.8% | ||
| Stability (higher is calmer) | 30 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 39.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -51.8% | ||
| Liquidity | 52 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.94M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 64 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.6% | ||
| Years with dividends | 6 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +2.6% |
|---|---|
| 1 month | +12.8% |
| 3 months | +9.5% |
| 6 months | −29.1% |
| 1 year | −43.4% |
| 3 years | −49.7% |
| 5 years | −58.9% |
Signals
| 50-day / 200-day average | 74.70 / 93.97 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.56 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Jul 2026 | USD 0.5300 |
| 17 Apr 2026 | USD 0.5300 |
| 19 Jan 2026 | USD 0.5300 |
| 30 Oct 2025 | USD 0.5000 |
| 17 Jul 2025 | USD 0.5000 |
| 17 Apr 2025 | USD 0.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.